Abstract
This chapter aims to provide the readers a comprehensive review of the current trends and approaches used in the development of ocular drug delivery systems. After the introduction to the topic, the chapter begins with a brief description of the common anatomical and physiological factors that are barriers to ocular drug transport and presents a persistent challenge to the development of formulations targeted to ophthalmic tissues. Further, traditional as well as relatively newer approaches used in the development of ocular formulations are discussed. Approaches such as viscosity modifiers, penetration enhancers, liposomal delivery, niosomes, microemulsions, prodrugs, and nanotechnology-derived approaches are extensively reviewed. These approaches are described with respect to the materials, formulation development, formulation performance, relative advantages and drawbacks, and recent advances in the technology. Additionally, the design approaches for the modified ocular drug delivery such as ocular implants, inserts, lenses, and ocular shields are described with respect to the formulation development. Finally, ocular drug delivery systems that are relatively newer or employed less frequently such as intravitreal injections, ocular iontophoresis, etc. are discussed. All approaches described are supported with relevant examples and up-to-date literature reports.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Patel PB et al (2010) Ophthalmic drug delivery system: challenges and approaches. Syst Rev Pharm 1(2):113–120
Peyman GA, Ganiban GJ (1995) Delivery systems for intraocular routes. Adv Drug Deliv Rev 16(1):107–123
Janoria KG et al (2007) Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4(4):371–388
Pal Kaur I, Kanwar M (2002) Ocular preparations: the formulation approach. Drug Dev Ind Pharm 28(5):473–493
Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 87(12):1479–1488
Keister JC et al (1991) Limits on optimizing ocular drug delivery. J Pharm Sci 80(1):50–53
Kaur IP, Kanwar M (2002) Ocular preparations: the formulation approach. Drug Dev Ind Pharm 28(5):473–493
Meseguer G et al (1996) Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 12(4):481–488
Zaki I et al (1986) A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man. J Pharm Pharmacol 38(6):463–466
Deshpande AA, Heller J, Gurny R (1998) Bioerodible polymers for ocular drug delivery. Crit Rev Ther Drug Carrier Syst 15(4):40
Bottari F et al (1974) Influence of drug concentration on in vitro release of salicylic acid from ointment bases. J Pharm Sci 63(11):1779–1783
Rozier A et al (1989) Gelrite®: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm 57(2):163–168
Hui H-W, Robinson JR (1985) Ocular delivery of progesterone using a bioadhesive polymer. Int J Pharm 26(3):203–213
Stevens LE, Missel PJ, Lang JC (1992) Drug release profiles of ophthalmic formulations. 1. Instrumentation. Anal Chem 64(7):715–723
Cohen S et al (1997) A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 44(2–3):201–208
Lee VHL (1993) Ophthalmic drug delivery systems. Precorneal Corneal and Postcorneal factors. In: Mitra AK (ed) Marcel Dekker, New York, pp 59–82
Lee VHL (1993) Biopharmaceutics of ocular drug delivery. Formulation Approaches to Improve Ocular Bioavailability. In: Edman P (ed) CRC Press, Boca Raton, pp 121–143
Liaw J, Robinson JR (1992) The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers. Int J Pharm 88(1–3):125–140
Sasaki H et al (1995) Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm Res 12(8):1146–1150
Sasaki H et al (1995) Penetration of β-blockers through ocular membranes in a1bino rabbits. J Pharm Pharmacol 47(1):17–21
Marshall W, Klyce D (1983) Cellular and paracellular pathway resistances in the ‘tight’ Cl−-secreting epithelium of rabbit cornea. J Membr Biol 73(3):275–282
Lee VHL (1990) Mechanisms and facilitation of corneal drug penetration. J Control Release 11(1–3):79–90
Chiou GCY, Chuang CY (1989) Improvement of systemic absorption of insulin through eyes with absorption enhancers. J Pharm Sci 78(10):815–818
Godbey REW, Green K, Hull DS (1979) Influence of cetylpyridinium chloride on corneal permeability to penicillin. J Pharm Sci 68(9):1176–1178
Higaki K, Takeuchi M, Nakano M (1996) Estimation and enhancement of in vitro corneal transport of S-1033, a novel antiglaucoma medication. Int J Pharm 132(1–2):165–173
Marsh RJ, Maurice DM (1971) The influence of non-ionic detergents and other surfactants on human corneal permeability. Exp Eye Res 11(1):43–48
Mikkelson TJ, Chrai SS, Robinson JR (1973) Competitive inhibition of drug-protein interaction in eye fluids and tissues. J Pharm Sci 62(12):1942–1945
Morimoto K, Nakai T, Morisaka K (1987) Evaluation of permeability enhancement of hydrophilic compounds and macromolecular compounds by bile salts through rabbit corneas in-vitro. J Pharm Pharmacol 39(2):124–126
Sasaki H et al (1995) Ophthalmic preservatives as absorption promoters for ocular drug delivery. J Pharm Pharmacol 47(9):703–707
Sasaki H et al (1994) Effect of preservatives on systemic delivery of insulin by ocular instillation in rabbits. J Pharm Pharmacol 46(11):871–875
Tang-Liu DDS et al (1994) Effects of four penetration enhancers on corneal permeability of drugs in vitro. J Pharm Sci 83(1):85–90
Van Santvliet L, Ludwig A (1998) The influence of penetration enhancers on the volume instilled of eye drops. Eur J Pharm Biopharm 45(2):189–198
Lee VH, Robinson JR (1986) Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 2(1):67–108
Green K (1993) Biopharmaceutics in ocular drug delivery. The effects of preservatives on corneal permeability of drugs. In: Edman P (ed) CRC PRess, Boca Raton, pp 43–49
Pfister RR, Burstein N (1976) The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol 15(4):246–259
Hochman J, Artursson P (1994) Mechanisms of absorption enhancement and tight junction regulation. J Control Release 29(3):253–267
Saettone MF et al (1996) Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four Î2-blockers, and in vitro/in vivo toxic activity. Int J Pharm 142(1):103–113
Grass GM, Robinson JR (1988) Mechanisms of corneal drug penetration I: in vivo and in vitro kinetics. J Pharm Sci 77(1):3–14
Newton C, Gebhardt BM, Kaufman HE (1988) Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 29(2):208–215
Green K et al (1987) Detergent penetration into young and adult rabbit eyes: comparative pharmacokinetics. Cutan Ocul Toxicol 6(2):89–107
Grass GM, Robinson JR (1984) Relationship of chemical structure to corneal penetration and influence of low-viscosity solution on ocular bioavailability. J Pharm Sci 73(8):1021–1027
Ismail IM et al (1992) Comparison of azone and hexamethylene lauramide in toxicologic effects and penetration enhancement of cimetidine in rabbit eyes. Pharm Res 9(6):817–821
Merkus FWHM et al (1993) Absorption enhancers in nasal drug delivery: efficacy and safety. J Control Release 24(1–3):201–208
Rojanasakul Y, Liaw J, Robinson JR (1990) Mechanisms of action of some penetration enhancers in the cornea: laser scanning confocal microscopic and electrophysiology studies. Int J Pharm 66(1–3):131–142
Komatsu A et al (1988) Application of lipid microsphere drug delivery system to steroidal ophthalmic preparation. Jpn J Ophthalmol 32(1):41–43
Oppenheim RC (1980) Drug delivery systems characteristics and biomedical applications. Nanoparticle. In: Juliano RJ (ed) Oxford University Press, New York, pp 177–188
Meisner D, Mezei M (1995) Liposome ocular delivery systems. Adv Drug Deliv Rev 16(1):75–93
Dharma SK, Fishman PH, Peyman GA (1986) A preliminary study of corneal penetration of 125l-labelled idoxuridine liposome. Acta Ophthalmol (Copenh) 64(3):298–301
Smolin G et al (1981) Idoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol 91(2):220–225
Schaeffer HE, Krohn DL (1982) Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 22(2):220–227
Shek PN, Barber RF (1987) Liposomes are effective carriers for the ocular delivery of prophylactics. Biochim Biophys Acta Biomembr 902(2):229–236
Al-Muhammed J et al (1996) In-vivo studies on dexamethasone sodium phosphate liposomes. J Microencapsul 13(3):293–305
El-Gazayerly ON, Hikal AH (1997) Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm 158(2):121–127
Milani JK et al (1993) Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology 100(6):890–896
Lee VHL et al (1985) Ocular drug bioavailability from topically applied liposomes. Surv Ophthalmol 29(5):335–348
Liddell MR et al (2007) Evaluation of glass dissolution vessel dimensions and irregularities. Dissolution Technol 14(1):28–33
Durrani AM et al (1992) Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system. Int J Pharm 88(1–3):409–415
Pleyer U et al (1994) Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Curr Eye Res 13(3):177–181
Kaur IP et al (2004) Vesicular systems in ocular drug delivery: an overview. Int J Pharm 269(1):1–14
Uchegbu IF, Vyas SP (1998) Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172(1–2):33–70
Carafa M et al (1998) Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles. Int J Pharm 160(1):51–59
Carafa M, Santucci E, Lucania G (2002) Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm 231(1):21–32
Abdelbary G, El-gendy N (2008) Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech 9(3):740–747
Vyas SP et al (1998) Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 53(7):466–469
Pandita A, Sharma P (2013) Pharmacosomes: an emerging novel vesicular drug delivery system for poorly soluble synthetic and herbal drugs. ISRN Pharm 2013:1–10
Fialho SL, da Silva-Cunha A (2004) New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol 32(6):626–632
Vandamme TF (2002) Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res 21(1):15–34
Hasse A, Keipert S (1997) Development and characterization of microemulsions for ocular application. Eur J Pharm Biopharm 43(2):179–183
Klang S, Abdulrazik M, Benita S (2000) Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 5(4):521–532
Chan J et al (2007) Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm 328(1):65–71
Kapoor Y, Chauhan A (2008) Ophthalmic delivery of cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm 361(1–2):222–229
G.Wilson C, Y.P.Zhu, P.Kurmala, L.S.Rao, B.Dhillon. Ophthalmic Drug Delivery. In: M.Hillery A, W.Lloyd A, Swarbrick J, editors. Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. London: Taylor & Francis; 2005. p. 298–319
Pignatello R et al (2002) Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 23(15):3247–3255
Adibkia K et al (2007) Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther 23(5):421–432
Adibkia K et al (2007) Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 15(6):407–416
Kassem MA et al (2007) Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340(1–2):126–133
Pignatello R et al (2006) Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 7(1):E192–E198
Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13(3–4):144–151
Sakurai E et al (2001) Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 33(1):31–36
Gan L et al (2013) Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 18(5–6):290–297
Bourges JL et al (2003) Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 44(8):3562–3569
Li VH et al (1986) Ocular drug delivery of progesterone using nanoparticles. J Microencapsul 3(3):213–218
Cavalli R et al (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238(1–2):241–245
Amrite AC et al (2008) Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis 14:150–160
Irache JM et al (2005) Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 5(3):293–305
Calvo P, Vila-Jato JL, Alonso MJ (1996) Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 85(5):530–536
De Campos AM et al (2003) The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 20(1):73–81
Xu J et al (2007) Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther 23(6):527–540
Motwani SK et al (2008) Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 68(3):513–525
Arnedo A et al (2004) Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Control Release 94(1):217–227
Gaudana R et al (2009) Recent perspectives in ocular drug delivery. Pharm Res 26(5):1197–1216
Gunda S, Hariharan S, Mitra AK (2006) Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. J Ocul Pharmacol Ther 22(6):465–476
Majumdar S et al (2005) Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocul Pharmacol Ther 21(6):463–474
Kansara V, Hao Y, Mitra AK (2007) Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. J Ocul Pharmacol Ther 23(4):321–334
Janoria KG, Mitra AK (2007) Effect of lactide/glycolide ratio on the in vitro release of ganciclovir and its lipophilic prodrug (GCV-monobutyrate) from PLGA microspheres. Int J Pharm 338(1–2):133–141
Dias C et al (2002) Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: an evaluation using ocular microdialysis and LC-MS. Curr Eye Res 25(4):243–252
Anand BS et al (2003) In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol Vis Sci 44(6):2529–2534
Katragadda S, Talluri RS, Mitra AK (2006) Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. J Ocul Pharmacol Ther 22(2):110–120
Doukas J et al (2008) Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 216(1):29–37
Al-Ghananeem AM, Crooks PA (2007) Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules 12(3):373–388
Lallemand F et al (2007) Biological conversion of a water-soluble prodrug of cyclosporine A. Eur J Pharm Biopharm 67(2):555–561
Juntunen J, Jarvinen T, Niemi R (2005) In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. J Pharm Pharmacol 57(9):1153–1157
Nambu H et al (2003) Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 44(8):3650–3655
Takahashi K et al (2003) Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 44(1):409–415
Punch PI et al (1987) The release of insoluble antibiotics from collagen ocular inserts in vitro and their insertion into the conjunctival sac of cattle. J Vet Pharmacol Ther 10(1):37–42
Rawas-Qalaji M, Williams CA (2012) Advances in ocular drug delivery. Curr Eye Res 37(5):345–356
Jalil R-U (1990) Biodegradable poly(lactic acid) and poly (lactide-co-glycolide) polymers in sustained drug delivery. Drug Dev Ind Pharm 16(16):2353–2367
Hashizoe M et al (1994) SCleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch Ophthalmol 112(10):1380–1384
Kimura H et al (1994) A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci 35(6):2815–2819
Kunou N et al (1995) Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J Control Release 37(1–2):143–150
Sanborn GE et al (1992) Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 110(2):188–195
Gurtler F, Gurny R (1995) Patent literature review of ophthalmic inserts. Drug Dev Ind Pharm 21(1):1–18
Chien YW (1992) Ocular drug delivery and delivery systems. In: Chien YW (ed) Novel drug delivery systems, 2nd edn. Taylor and Francis, New York
Karthikeyan D et al (2008) The concept of ocular inserts as drug delivery systems: an overview. Asian J Pharm 2(4):192–200
Khar RK, Vyas SP (2002) Targeted and controlled drug delivery novel carrier systems. In: Khar RK, Vyas SP (eds), 1st edn. CBS Publishers and Distributors, New Delhi
Saettone MF, Salminen L (1995) Ocular inserts for topical delivery. Adv Drug Deliv Rev 16(1):95–106
Sahane NK et al (2010) Ocular inserts: a review. J Pharm Res 3(1):57–64
El-Shanawany S (1992) Ocular delivery of pilocarpine from ocular inserts. Pharma Sci 2(4):337–341
Gurtler F et al (1995) Long-acting soluble bioadhesive ophthalmic drug insert (BODI) containing gentamicin for veterinary use: optimization and clinical investigation. J Control Release 33(2):231–236
Pollack IP, Quigley HA, Harbin TS (1976) The Ocusert pilocarpine system: advantages and disadvantages. South Med J 69(10):1296–1298
Johansen S, Prause JU, Rask-Pedersen E (1996) I: a bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension. Acta Ophthalmol Scand 74(3):253–258
Urtti A, Salminen L, Miinalainen O (1985) Systemic absorption of ocular pilocarpine is modified by polymer matrices. Int J Pharm 23(2):147–161
Urtti A, Juslin M, Miinalainen O (1985) Pilocarpine release from hydroxypropyl-cellulose-polyvinylpyrrolidone matrices. Int J Pharm 25(2):165–178
Vasantha V, Sehgal PK, Rao KP (1988) Collagen ophthalmic inserts for pilocarpine drug delivery system. Int J Pharm 47(1–3):95–102
Attia MA, Kassem MA, Safwat SM (1988) In vivo performance of [3H]dexamethasone ophthalmic film delivery systems in the rabbit eye. Int J Pharm 47(1–3):21–30
Darougar S (1992) Ocular insert for the fornix. In: U.S.P.A.T. Office (ed) Google. Google Patents, USA
Urtti A et al (1994) Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm Res 11(9):1278–1282
Dumitriu S et al (1988) Polycomponent ophthalmic inserts with polysaccharide support. J Bioact Compat Polym 3(4):370–389
Kalenak JW, Zakov ZN (1994) Presumed sudden leakage of a pilocarpine ocusert and rhegmatogenous retinal detachment. J Glaucoma 3(2):152–153
Kushnick H, Liebmann JM, Ritch R (1996) Systemic pilocarpine toxicity from ocusert leakage. Arch Ophthalmol 114(11):1432–1432
Hitoshi S et al (1993) Drug release from an ophthalmic insert of a beta-blocker as an ocular drug delivery system. J Control Release 27(2):127–137
Fazly Bazzaz BS et al (2014) Preparation, characterization and antimicrobial study of a hydrogel (soft contact lens) material impregnated with silver nanoparticles. Cont Lens Anterior Eye 37(3):149–152
Maichuk YF, Erichev VP (1981) Soluble ophthalmic drug inserts with pilocarpine: experimental and clinical study. Glaucoma 3:239–242
Baeyens V et al (1998) Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J Control Release 52(1–2):215–220
Aiache JM et al (1997) The formulation of drug for ocular administration. J Biomater Appl 11(3):329–348
Kamath U, Singh U, Udupa N (1993) Evaluation of ciprofloxacin hydrochloride ocular preparations. Ind J Pharm Sci 55(4):148–150
Mundada AS, Shrikhande BK (2006) Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev Ind Pharm 32(4):443–448
Mundada AS, Shrikhande BK (2008) Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 33(5):469–475
Gurtler F, Gurny R (1998) Bioadhesive ophthalmic insert. In: U.S.P.A.T. Office, Vetoquinol SA (ed) Google patents, Lure, USA
Saettone MF et al (1992) Controlled release of pilocarpine from coated polymeric ophthalmic inserts prepared by extrusion. Int J Pharm 86(2–3):159–166
Willoughby CE, Batterbury M, Kaye SB (2002) Collagen corneal shields. Surv Ophthalmol 47(2):174–182
Poland DE, Kaufman HE (1988) Clinical uses of collagen shields. J Cataract Refract Surg 14(5):489–491
Kaufman HE (1988) Collagen shield symposium. J Cataract Refract Surg 14(5):487–488
Kaufman HE et al (1994) Collagen-based drug delivery and artificial tears. J Ocul Pharmacol 10(1):17–27
Bloomfield SE et al (1978) Soluble gentamicin ophthalmic inserts as a drug delivery system. Arch Ophthalmol 96(5):885–887
Sawusch MR et al (1988) Use of collagen corneal shields in the treatment of bacterial keratitis. Am J Ophthalmol 106(3):279–281
Assil KK et al (1992) Efficacy of tobramycin-soaked collagen shields vs tobramycin eyedrop loading dose for sustained treatment of experimental Pseudomonas aeruginosa-induced keratitis in rabbits. Am J Ophthalmol 113(4):418–423
Clinch TE et al (1992) Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis. CLAO J 18(4):245–247
O’Brien TP et al (1988) Use of collagen corneal shields versus soft contact lenses to enhance penetration of topical tobramycin. J Cataract Refract Surg 14(5):505–507
McDonnell PJ (1998) Method for preventing keratocyte loss. In: U.S.P.A.T. Office (ed) Google patents. University of Southern California (Los Angeles), USA
Sintzel MB et al (1996) Biomaterials in ophthalmic drug delivery. Eur J Pharm Biopharm 42(6):358–374
OASIS® Medical, I. SOFT SHIELD collagen corneal shield 2014 [cited 2014 September 22, 2014]; Widest range of dissolution rates available. Thin, purified collagen. 14.5-mm diameter shield. Accurate and consistent dissolution times]. Available from: http://oasismedical.com/soft-shield-collagen-corneal-shield.html
Lawrenson JG et al (1993) A comparison of the efficacy and duration of action of topically applied proxymetacaine using a novel ophthalmic delivery system versus eye drops in healthy young volunteers. Br J Ophthalmol 77(11):713–715
Greaves JL, Wilson CG (1993) Treatment of diseases of the eye with mucoadhesive delivery systems. Adv Drug Deliv Rev 11(3):349–383
Greaves JL et al (1992) Scintigraphic studies on the corneal residence of a new ophthalmic delivery system (NODS): rate of clearance of a soluble marker in relation to duration of pharmacological action of pilocarpine. Br J Clin Pharmacol 33(6):603–609
Bentley PH (1990) A new ophthalmic delivery system (NODS). In: 9th pharmaceutical technology conference. Veldhoven, Netherlands
Kelly JA et al (1989) Relative bioavailability of pilocarpine from a novel ophthalmic delivery system and conventional eyedrop formulations. Br J Ophthalmol 73(5):360–362
Diestelhorst M, Krieglstein GK (1994) The ocular tolerability of a new ophthalmic drug delivery system (NODS). Int Ophthalmol 18(1):1–4
Alani S, Hammerstein W (1990) The ophthalmic rod – a new drug-delivery system II. Graefes Arch Clin Exp Ophthalmol 228(4):302–304
Gwon A et al (1986) Ophthalmic rods. Ophthalmology 93(9):82–85
Eller MG et al (1985) Topical carbonic anhydrase inhibitors IV: relationship between excised corneal permeability and pharmacokinetic factors. J Pharm Sci 74(5):525–529
Maren TH et al (1987) Ocular pharmacology of methazolamide analogs: distribution in the eye and effects on pressure after topical application. J Pharmacol Exp Ther 241(1):56–63
Putnam ML et al (1987) Ocular disposition of aminozolamide in the rabbit eye. Invest Ophthalmol Vis Sci 28(8):1373–1382
Wilson CG, Olejnik O, Hardy JG (1983) Precorneal drainage of polyvinyl alcohol solutions in the rabbit assessed by gamma scintigraphy. J Pharm Pharmacol 35(7):451–454
Ludwig A, Ooteghem MV (1986) The study of the precorneal dynamics of ophthalmic solutions by fluorophotometry. Pharm Acta Helv 61(8):236–240
Ludwig A, Van Ooteghem M (1989) The evaluation of viscous ophthalmic vehicles by slit lamp fluorophotometry in humans. Int J Pharm 54(2):95–102
Shen YC et al (2014) Pharmacokinetics and safety of intravitreal caspofungin. Antimicrob Agents Chemother 2014(22):03324–14
Haller JA et al (2014) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 6420(14):00689–7
Inoue M et al (2014) Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life. Clin Ophthalmol 8:1711–1716
Ausayakhun S et al (2005) Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J Med Assoc Thai 88(9):S15–S20
Ornek N, Ornek K, Erbahceci IE (2014) Corneal and conjunctival sensitivity changes following intravitreal ranibizumab injection in diabetic retinopathy. J Ocul Pharmacol Ther 2014:22
Aslan Bayhan S et al (2014) Marginal keratitis after intravitreal injection of ranibizumab. Cornea 2014:12
Parkinson TM et al (2003) Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther 19(2):145–151
Vollmer DL et al (2002) In vivo transscleral iontophoresis of amikacin to rabbit eyes. J Ocul Pharmacol Ther 18(6):549–558
Frucht-Pery J et al (2006) Iontophoretic treatment of experimental pseudomonas keratitis in rabbit eyes using gentamicin-loaded hydrogels. Cornea 25(10):1182–1186
Hobden JA et al (1989) Tobramycin iontophoresis into corneas infected with drug-resistant Pseudomonas aeruginosa. Curr Eye Res 8(11):1163–1169
Hobden JA et al (1990) Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. Invest Ophthalmol Vis Sci 31(10):1940–1944
Eljarrat-Binstock E et al (2005) Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release 106(3):386–390
Berdugo M et al (2003) Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev 13(2):107–114
Barza M, Peckman C, Baum J (1986) Transscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmology 93(1):133–139
Behar-Cohen FF et al (2002) Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res 74(1):51–59
Grossman RE, Chu DF, Lee DA (1990) Regional ocular gentamicin levels after transcorneal and transscleral iontophoresis. Invest Ophthalmol Vis Sci 31(5):909–916
Sarraf D et al (1993) Transscleral iontophoresis of foscarnet. Am J Ophthalmol 115(6):748–754
Lam TT et al (1994) Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis. J Ocul Pharmacol 10(3):571–575
Hayden BC et al (2004) Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci 45(10):3644–3649
Ghate D et al (2007) Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci 48(5):2230–2237
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Dave, V.S. (2016). Formulation Approaches for Ocular Drug Delivery. In: Pathak, Y., Sutariya, V., Hirani, A. (eds) Nano-Biomaterials For Ophthalmic Drug Delivery. Springer, Cham. https://doi.org/10.1007/978-3-319-29346-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-29346-2_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29344-8
Online ISBN: 978-3-319-29346-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)